Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.
Animals
Blood Vessels
/ pathology
Breast
/ metabolism
Class I Phosphatidylinositol 3-Kinases
/ genetics
Class Ia Phosphatidylinositol 3-Kinase
/ genetics
Cyclin-Dependent Kinase Inhibitor p15
/ genetics
Cyclin-Dependent Kinase Inhibitor p16
/ genetics
Dogs
Female
Genome
/ genetics
Genomics
Hemangiosarcoma
/ genetics
Humans
Mutation
/ genetics
Tumor Suppressor Protein p53
/ genetics
Viscera
/ metabolism
Exome Sequencing
Journal
Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
22
02
2019
revised:
12
07
2019
accepted:
25
09
2019
pubmed:
2
10
2019
medline:
23
6
2020
entrez:
2
10
2019
Statut:
ppublish
Résumé
Angiosarcoma is a highly aggressive cancer of blood vessel-forming cells with few effective treatment options and high patient mortality. It is both rare and heterogenous, making large, well-powered genomic studies nearly impossible. Dogs commonly suffer from a similar cancer, called hemangiosarcoma, with breeds like the golden retriever carrying heritable genetic factors that put them at high risk. If the clinical similarity of canine hemangiosarcoma and human angiosarcoma reflects shared genomic etiology, dogs could be a critically needed model for advancing angiosarcoma research. We assessed the genomic landscape of canine hemangiosarcoma via whole-exome sequencing (47 golden retriever hemangiosarcomas) and RNA sequencing (74 hemangiosarcomas from multiple breeds). Somatic coding mutations occurred most frequently in the tumor suppressor
Identifiants
pubmed: 31570656
pii: 1541-7786.MCR-19-0221
doi: 10.1158/1541-7786.MCR-19-0221
pmc: PMC7067513
mid: NIHMS1540746
doi:
Substances chimiques
Cyclin-Dependent Kinase Inhibitor p15
0
Cyclin-Dependent Kinase Inhibitor p16
0
Tumor Suppressor Protein p53
0
PIK3R1 protein, human
EC 2.7.1.-
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
Class Ia Phosphatidylinositol 3-Kinase
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2410-2421Subventions
Organisme : NCI NIH HHS
ID : R03 CA191713
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA077598
Pays : United States
Organisme : NIH HHS
ID : R24 OD018250
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211249
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA218570
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Oncol Rep. 2015 Jan;33(1):119-24
pubmed: 25394563
Nucleic Acids Res. 2015 Jan;43(Database issue):D805-11
pubmed: 25355519
Environ Health Perspect. 2002 Oct;110 Suppl 5:883-6
pubmed: 12426152
Ann Surg Oncol. 2007 Jun;14(6):1953-67
pubmed: 17356953
Exp Mol Med. 2000 Sep 30;32(3):101-9
pubmed: 11048639
PLoS One. 2017 Nov 30;12(11):e0188667
pubmed: 29190660
Acta Vet Hung. 2002;50(2):157-60
pubmed: 12113170
J Am Vet Med Assoc. 2015 Aug 15;247(4):393-403
pubmed: 26225611
Am J Pathol. 2014 Apr;184(4):985-995
pubmed: 24525151
Cancer. 1981 Oct 15;48(8):1907-21
pubmed: 7197190
Mod Pathol. 2014 Jan;27 Suppl 1:S30-8
pubmed: 24384851
APMIS. 2012 Aug;120(8):635-9
pubmed: 22779686
J Vet Intern Med. 1993 Nov-Dec;7(6):370-6
pubmed: 8114034
Chromosome Res. 2014 Sep;22(3):305-19
pubmed: 24599718
Vet Comp Oncol. 2015 Sep;13(3):237-45
pubmed: 23611531
Nucleic Acids Res. 2003 Jul 1;31(13):3812-4
pubmed: 12824425
Genes Chromosomes Cancer. 2009 Apr;48(4):330-9
pubmed: 19145645
Nat Rev Cancer. 2018 Nov;18(11):696-705
pubmed: 30293088
J Am Vet Med Assoc. 1985 Jan 1;186(1):56-8
pubmed: 4038395
Vet Sci. 2015 Nov 06;2(4):388-405
pubmed: 29061949
Int J Biochem Cell Biol. 2018 Mar;96:135-147
pubmed: 28941747
Clin Chem. 2015 Jan;61(1):64-71
pubmed: 25421801
Nucleic Acids Res. 2012 May;40(10):e72
pubmed: 22323520
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
PLoS One. 2017 Oct 31;12(10):e0186649
pubmed: 29088295
Oncogene. 2012 Aug 9;31(32):3655-66
pubmed: 22120714
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Science. 1997 Jun 20;276(5320):1848-50
pubmed: 9188528
Am J Hum Genet. 2003 Dec;73(6):1240-9
pubmed: 14639529
Lancet. 1979 Nov 24;2(8152):1120-3
pubmed: 91848
Nat Genet. 2014 Apr;46(4):376-379
pubmed: 24633157
Oncotarget. 2018 Jan 19;9(11):10042-10053
pubmed: 29515789
Cancer. 2012 Dec 1;118(23):5878-87
pubmed: 22648906
Nature. 1995 Oct 26;377(6551):695-701
pubmed: 7477259
Cell. 2017 Aug 10;170(4):605-635
pubmed: 28802037
Science. 2004 Apr 23;304(5670):554
pubmed: 15016963
Nat Commun. 2015 Sep 25;6:8383
pubmed: 26403419
Nat Rev Cancer. 2006 Mar;6(3):184-92
pubmed: 16453012
J Comp Pathol. 1978 Oct;88(4):585-95
pubmed: 568633
Crit Rev Oncol Hematol. 2011 Nov;80(2):257-63
pubmed: 21055965
Curr Treat Options Oncol. 2018 Mar 8;19(3):14
pubmed: 29520447
PLoS Genet. 2015 Feb 02;11(2):e1004922
pubmed: 25642983
JAMA. 1974 Oct 7;230(1):64-8
pubmed: 4479235
Cancer Res. 2014 Nov 1;74(21):6173-83
pubmed: 25252913
Sarcoma. 2005;9(3-4):137-40
pubmed: 18521421
Hematol Oncol Clin North Am. 2013 Oct;27(5):975-88
pubmed: 24093171
Lancet Oncol. 2010 Oct;11(10):983-91
pubmed: 20537949
Oncotarget. 2015 Nov 3;6(34):36041-52
pubmed: 26440310
Ann Surg. 2010 Jun;251(6):1098-106
pubmed: 20485141
Vet Comp Oncol. 2012 Sep;10(3):223-35
pubmed: 22594682
Anticancer Res. 2017 Feb;37(2):781-785
pubmed: 28179330
Vet Pathol. 2005 Sep;42(5):618-32
pubmed: 16145208
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087
Oncology. 1975;31(2):61-75
pubmed: 1239702
BMC Vet Res. 2015 Jun 11;11:131
pubmed: 26062540
Biochimie. 2009 Mar;91(3):320-8
pubmed: 19022332
Database (Oxford). 2011 Jul 23;2011:bar030
pubmed: 21785142
NPJ Precis Oncol. 2017 Apr 20;1(1):11
pubmed: 29872699
Mol Cancer Ther. 2017 May;16(5):956-965
pubmed: 28193671